TY - JOUR
T1 - Epidemiology and predisposing factors of post-COVID venous thrombosis
T2 - A concise review
AU - Lippi, Giuseppe
AU - Favaloro, Emmanuel J
N1 - Publisher Copyright:
© 2023 Thieme Medical Publishers, Inc.. All rights reserved.
PY - 2024
Y1 - 2024
N2 - Long-coronavirus disease 2019 (COVID-19) represents a heterogeneous clinical syndrome characterized by a pathologic continuum of signs, symptoms, and also laboratory/radiologic abnormalities that may persist for a long time after recovering from an acute severe acute respiratory syndrome-coronavirus disease 2 infection. Among the various components of this postviral condition, the risk of venous thromboembolism in patients hospitalized for COVID-19 remains considerably higher after discharge, especially in older individuals, in men, in patients with longer hospital stays and more aggressive treatment (e.g., mechanical ventilation and/or intensive care), when thromboprophylaxis is not used, and in those with a persistent prothrombotic state. Patients who have these predisposing factors should be monitored more closely to intercept any thrombosis that may occur in a post-COVID time-related manner but may also benefit from extended thromboprophylaxis and/or antiplatelet therapy.
AB - Long-coronavirus disease 2019 (COVID-19) represents a heterogeneous clinical syndrome characterized by a pathologic continuum of signs, symptoms, and also laboratory/radiologic abnormalities that may persist for a long time after recovering from an acute severe acute respiratory syndrome-coronavirus disease 2 infection. Among the various components of this postviral condition, the risk of venous thromboembolism in patients hospitalized for COVID-19 remains considerably higher after discharge, especially in older individuals, in men, in patients with longer hospital stays and more aggressive treatment (e.g., mechanical ventilation and/or intensive care), when thromboprophylaxis is not used, and in those with a persistent prothrombotic state. Patients who have these predisposing factors should be monitored more closely to intercept any thrombosis that may occur in a post-COVID time-related manner but may also benefit from extended thromboprophylaxis and/or antiplatelet therapy.
KW - COVID-19
KW - SARS-CoV-2
KW - deep vein thrombosis
KW - pulmonary embolism
KW - venous thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85165264641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165264641&partnerID=8YFLogxK
U2 - 10.1055/s-0043-1770051
DO - 10.1055/s-0043-1770051
M3 - Article
C2 - 37327881
SN - 0094-6176
VL - 50
SP - 271
EP - 274
JO - Seminars in Thrombosis and Hemostasis
JF - Seminars in Thrombosis and Hemostasis
IS - 2
ER -